Diabetes Tech:  A Catalyst Rich Sector with a Dazzling Future

Early last year, MD+DI (Medical Device and Design Industry) predicted that 2022 would be the biggest year yet for diabetes tech – and they were not wrong.  If the latest news and analyst takeaways from the sector’s biggest 2023 conference is any indication; however, they have not seen anything yet.

Marie Thibault, a Medtech analyst at BTIG, said overall attendance at the American Diabetes Association (ADA) 83rd Scientific Sessions seemed low compared to pre-COVID and other medical meetings she has attended this year.  However, analyst and investor attendance at ADA was particularly high, she noted in a report in late June 2023.  “It is clear diabetes tech remains a high priority for the medtech investment community, in part because of the numerous catalysts and rapidly shifting market dynamics,” Thibault wrote.  “We remain bullish on the space and expect sales growth rates to keep outpacing most of medtech.”

REFERENCE:  MD+DI (Medical Device and Design Industry); 27 JUN 2023; Amanda Pedersen